Industry Odisha Bureau, Oct 25: In an early trial, J&J’s experimental pill cut PSA levels in most evaluable patients. Imaging showed tumours shrinking or disappearing in many. Larger studies must still confirm any lasting benefit.
Johnson & Johnson’s experimental prostate cancer drug shrank tumours in an early-stage trial. In some patients, tumours disappeared altogether, the company said on Saturday. The once-daily pill, JNJ-6143, was tested in men with advanced disease. All had already received multiple treatments. Signs of activity in such heavily treated patients carry clinical interest. Options typically narrow once earlier therapies stop working.
The strongest signals came at the 50-milligram dose. Among 31 evaluable patients, 77% saw PSA levels fall by at least half. In 48%, PSA dropped by at least 90%. PSA, or prostate-specific antigen, is a blood marker doctors use to track the disease. A falling PSA suggests the drug is acting on the cancer. It does not, on its own, prove patients will live longer.
Imaging offered a second, more direct measure. Among patients whose tumours could be measured on scans, 69% had confirmed responses. These included complete responses, where visible tumours disappeared, and partial ones, where they shrank. The 69% figure covers only this imaging-evaluable group, not every participant. A complete response on scans also differs from a permanent remission or cure.
J&J describes the drug’s approach as novel. It aims to kill cancer cells selectively by disrupting a protein they need to survive. That targeted design is intended to spare healthy cells. Selective intent does not rule out side effects, as the trial showed. A J&J spokesperson said it adds a new mechanism to the company’s prostate cancer portfolio.
J&J gained the drug through its $3.05 billion purchase of Halda Therapeutics last year. Large drugmakers often buy biotech firms to secure promising experimental programmes. The deal value reflects Halda as a whole, not JNJ-6143 alone. J&J already markets prostate cancer medicines, so a new mechanism could broaden its offering. Such acquisitions help companies refresh oncology pipelines as older medicines mature.
Common side effects included nausea and raised cholesterol and triglyceride levels. One patient stopped treatment because of adverse effects. Severity data and longer follow-up will be needed for a full safety picture. Few discontinuations alone do not establish that a drug is well tolerated.
The data were presented at the European Society for Medical Oncology. Conference presentations allow early findings to reach clinicians quickly. They are not the same as peer-reviewed publications, and figures may later change.
The findings come from a small, early-stage study. Such trials mainly test safety, tolerability and suitable doses. They are not designed to show survival or quality-of-life benefits. Larger, potentially comparative studies would be needed before any regulatory approval. Responses must also prove durable over longer follow-up.
For now, JNJ-6143 remains an experimental medicine, not an approved therapy. Its early results give J&J a new line of research in prostate cancer. Clinical results will shape J&J’s decisions on how far to develop it. Whether it becomes a treatment option will depend on what larger trials show.
